Cannabis stocks just got a policy rocket boost

The sector finally got a tailwind

Cannabis stocks woke up and chose chaos. U.S. regulators moved to reclassify certain marijuana products under Schedule III, and that was enough to send Akanda and its peers into full-on meme-stock mode.

For investors, the big deal isn’t just the headline pop. Schedule III would mean cannabis is treated less like a hard-no substance and more like a regulated medical product, which could make research easier and the industry look a little less like it’s operating in a legal gray zone the size of Texas.

Why everyone’s suddenly smiling

The Department of Justice and DEA also kicked off an expedited process to consider broader reclassification from Schedule I, with an administrative hearing set for June 29, 2026. Translation: this isn’t just a one-day sugar rush — it’s a policy process that could keep giving the sector a reason to trade on hope.

A few things investors are watching:

• Better research access for FDA-approved and medical marijuana products
• More clarity for state-regulated operators
• A possible opening for U.S.-focused growth plans, which is why Tilray is already talking expansion

But don’t confuse a policy pop with a business model

Akanda’s move was eye-watering: the stock jumped 214% in one session and kept climbing after hours. But that kind of move can also get sketchy fast, especially with the RSI screaming overbought and the stock still trying to stabilize after a 1-for-4.5 reverse split earlier this month.

So yes, the policy news is real. No, that doesn’t mean every cannabis name has suddenly turned into a tidy growth machine. Big picture: this is a meaningful regulatory shift, but the sector still has to prove it can turn political momentum into actual cash flow.